Literature DB >> 30538158

Objective Versus Self-Reported Adherence to Airway Clearance Therapy in Cystic Fibrosis.

Gabriela R Oates1, Irena Stepanikova2, Steven M Rowe3,4, Stephanie Gamble5, Hector H Gutierrez3, William T Harris3.   

Abstract

BACKGROUND: Historically, studies of adherence to airway clearance therapy in cystic fibrosis (CF) have relied on self-reporting. We compared self-reported airway clearance therapy adherence to actual usage data from home high-frequency chest wall compressions (HFCWC) vests and identified factors associated with overestimation of adherence in self-reports.
METHODS: Pediatric patients who perform airway clearance therapy with a HFCWC vest were eligible to participate. Objective adherence data were obtained from the HFCWC device, which records cumulative utilization time. Two readings at least 5 weeks apart were collected. Objective adherence was recorded as a ratio of mean-to-prescribed daily use (%). Self-reported adherence data were collected with a caregiver survey at enrollment. Adherence rates were categorized as low (< 35% of prescribed), moderate (36-79% of prescribed), and high (≥ 80% of prescribed). An overestimation was present when self-reported adherence was at least one category higher than objective adherence.
RESULTS: In the final sample (N = 110), mean adherence by usage data was 61%. Only 35% of subjects (n = 38) were highly adherent, and 28% (n = 31) were low adherent. In contrast, 65% of subjects (n = 72) reported high adherence and only 8% (n = 9) reported low adherence (P < .001). Nearly half of self-reports (46%) overestimated adherence. In a multiple regression analysis, overestimation was associated with multiple airway clearance therapy locations (odds ratio 7.13, 95% CI 1.16-43.72, P = .034) and prescribed daily use ≥ 60 min (odds ratio 3.85, 95% CI 1.08-13.76, P < .038). Among subjects with prescribed daily airway clearance therapy ≥ 60 min, the odds of overestimating adherence increased 3-fold (odds ratio 3.04, 95% CI 1.17-7.87, P = .02) in a lower-income (< $50,000/y) environment.
CONCLUSIONS: Self-reports overestimated actual adherence to airway clearance therapy, and the overestimation increased with treatment occurring in multiple households and prescribed therapy duration. Among participants with prescribed airway clearance therapy ≥ 60 min, overestimation increased with lower income. Objective measures of adherence are needed, particularly for lower-income children and those receiving treatments in multiple locations.
Copyright © 2019 by Daedalus Enterprises.

Entities:  

Keywords:  adherence; airway clearance; chest physical therapy; cystic fibrosis; high-frequency chest wall compressions

Mesh:

Year:  2018        PMID: 30538158      PMCID: PMC6818680          DOI: 10.4187/respcare.06436

Source DB:  PubMed          Journal:  Respir Care        ISSN: 0020-1324            Impact factor:   2.258


  20 in total

1.  Objective Measurement of Adherence to Out-Patient Airway Clearance Therapy by High-Frequency Chest Wall Compression in Cystic Fibrosis.

Authors:  Christina L Mikesell; Robert R Kempainen; Theresa A Laguna; Jeremiah S Menk; Andrew R Wey; Philippe R Gaillard; Warren E Regelmann
Journal:  Respir Care       Date:  2017-04-19       Impact factor: 2.258

2.  Correlates of medication knowledge and adherence: findings from the residency research network of South Texas.

Authors:  Sandra Burge; Darryl White; Ellen Bajorek; Oralia Bazaldua; Juan Trevino; Theresa Albright; Frank Wright; Leo Cigarroa
Journal:  Fam Med       Date:  2005 Nov-Dec       Impact factor: 1.756

3.  Longitudinal association between medication adherence and lung health in people with cystic fibrosis.

Authors:  Michelle N Eakin; Andrew Bilderback; Michael P Boyle; Peter J Mogayzel; Kristin A Riekert
Journal:  J Cyst Fibros       Date:  2011-03-31       Impact factor: 5.482

4.  Respiratory medication adherence in chronic lung disease of prematurity.

Authors:  J Michael Collaco; Amanda J Kole; Kristin A Riekert; Michelle N Eakin; Sande O Okelo; Sharon A McGrath-Morrow
Journal:  Pediatr Pulmonol       Date:  2011-09-08

5.  A multi-method assessment of treatment adherence for children with cystic fibrosis.

Authors:  Avani C Modi; Crystal S Lim; Nami Yu; David Geller; Mary H Wagner; Alexandra L Quittner
Journal:  J Cyst Fibros       Date:  2006-05-05       Impact factor: 5.482

6.  Trajectories of adherence to airway clearance therapy for patients with cystic fibrosis.

Authors:  Avani C Modi; Amy E Cassedy; Alexandra L Quittner; Frank Accurso; Marci Sontag; Joni M Koenig; Richard F Ittenbach
Journal:  J Pediatr Psychol       Date:  2010-03-18

7.  Adherence to long-acting inhaled therapies among patients with chronic obstructive pulmonary disease (COPD).

Authors:  Laura M Cecere; Christopher G Slatore; Jane E Uman; Laura E Evans; Edmunds M Udris; Chris L Bryson; David H Au
Journal:  COPD       Date:  2012-04-12       Impact factor: 2.409

8.  Treatment compliance in children and adults with cystic fibrosis.

Authors:  Rosa Patricia Arias Llorente; Carlos Bousoño García; Juan José Díaz Martín
Journal:  J Cyst Fibros       Date:  2008-03-04       Impact factor: 5.482

9.  Patient adherence and medical treatment outcomes: a meta-analysis.

Authors:  M Robin DiMatteo; Patrick J Giordani; Heidi S Lepper; Thomas W Croghan
Journal:  Med Care       Date:  2002-09       Impact factor: 2.983

10.  Self-management in pediatric inflammatory bowel disease: A clinical report of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition.

Authors:  Kevin A Hommel; Rachel N Greenley; Michele Herzer Maddux; Wendy N Gray; Laura M Mackner
Journal:  J Pediatr Gastroenterol Nutr       Date:  2013-08       Impact factor: 2.839

View more
  1 in total

Review 1.  The future of cystic fibrosis care: a global perspective.

Authors:  Scott C Bell; Marcus A Mall; Hector Gutierrez; Milan Macek; Susan Madge; Jane C Davies; Pierre-Régis Burgel; Elizabeth Tullis; Claudio Castaños; Carlo Castellani; Catherine A Byrnes; Fiona Cathcart; Sanjay H Chotirmall; Rebecca Cosgriff; Irmgard Eichler; Isabelle Fajac; Christopher H Goss; Pavel Drevinek; Philip M Farrell; Anna M Gravelle; Trudy Havermans; Nicole Mayer-Hamblett; Nataliya Kashirskaya; Eitan Kerem; Joseph L Mathew; Edward F McKone; Lutz Naehrlich; Samya Z Nasr; Gabriela R Oates; Ciaran O'Neill; Ulrike Pypops; Karen S Raraigh; Steven M Rowe; Kevin W Southern; Sheila Sivam; Anne L Stephenson; Marco Zampoli; Felix Ratjen
Journal:  Lancet Respir Med       Date:  2019-09-27       Impact factor: 30.700

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.